Pediatric Cancer Genome Project

Pediatric Cancer Genome Project
Name	Pediatric Cancer Genome Project
Country	United States
Institution	St. Jude Children's Research Hospital; Washington University School of Medicine
Start	2010
End	2014
Funder	St. Jude Children's Research Hospital; Genome Institute

Pediatric Cancer Genome Project

The Pediatric Cancer Genome Project was a large-scale collaborative initiative to map genomic alterations in childhood cancers through comprehensive sequencing and integrative analysis. Launched as a partnership between St. Jude Children's Research Hospital and the Washington University School of Medicine, the project combined clinical samples, high-throughput sequencing, and bioinformatics to define mutation landscapes across pediatric malignancies. The effort aimed to provide foundational datasets for research communities, oncology consortia, and precision medicine programs at institutions such as National Cancer Institute, Broad Institute, and international pediatric oncology groups.

Background and Objectives

The project originated amid growing interest from leaders at St. Jude Children's Research Hospital and the Genome Institute at Washington University to address gaps highlighted by initiatives like the Human Genome Project, International Cancer Genome Consortium, and The Cancer Genome Atlas. Primary objectives included cataloguing somatic mutations, structural variants, and copy-number alterations in childhood tumors from entities represented by centers such as Dana-Farber Cancer Institute, Children's Hospital of Philadelphia, Memorial Sloan Kettering Cancer Center, and Great Ormond Street Hospital. Goals emphasized linking molecular discovery to clinical endpoints tracked by groups like Children's Oncology Group and the European Society for Paediatric Oncology. Funding, oversight, and ethical frameworks were informed by organizational partners including Howard Hughes Medical Institute and national regulators such as Food and Drug Administration for future translational pathways.

Study Design and Methods

The study used paired tumor-normal sequencing strategies adapted from platforms developed at Washington University School of Medicine and protocols refined at Broad Institute. Methods combined whole-genome sequencing, whole-exome sequencing, and transcriptome sequencing following pipelines influenced by standards from the 1000 Genomes Project and analytic approaches from Cancer Genome Atlas Research Network. Sample collection involved pathology workflows and consent processes coordinated with pediatric hospitals including Baylor College of Medicine and Seattle Children's Hospital. Bioinformatics pipelines integrated tools and resources originally developed at European Molecular Biology Laboratory, Wellcome Trust Sanger Institute, and commercial vendors, enabling identification of single-nucleotide variants, indels, copy-number changes, and gene fusions. Data quality control and variant curation leveraged collaborations with groups at Cold Spring Harbor Laboratory and computational groups at Massachusetts Institute of Technology.

Key Findings and Discoveries

Analyses revealed distinct mutational burdens and recurrent driver events in tumor types treated at centers like Children's Hospital of Philadelphia and St. Jude Children's Research Hospital, including novel fusions and mutations affecting pathways known from studies at Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, and Harvard Medical School. The project identified lineage-specific alterations with parallels to discoveries from The Cancer Genome Atlas, and highlighted the role of structural variants similar to findings at Sanger Institute. Significant discoveries included mutations in genes connected to developmental biology studied at Johns Hopkins University School of Medicine, links to transcriptional programs described at University of California, San Francisco, and new targets later evaluated by investigators at University of Pennsylvania Perelman School of Medicine and Stanford University School of Medicine. Cross-references to pediatric clinical cohorts from Great Ormond Street Hospital and molecular classifications used by Children's Oncology Group reshaped subtype definitions for leukemias, brain tumors, and sarcomas.

Clinical and Translational Impact

Findings informed clinical trial design at institutions such as Memorial Sloan Kettering Cancer Center and drug development partnerships involving companies with ties to National Cancer Institute translational programs and pharmaceutical collaborators. Genomic biomarkers discovered influenced biomarker-driven trials coordinated by European Society for Medical Oncology and pediatric trial consortia like Children's Oncology Group. Results prompted incorporation of sequencing assays into diagnostic workflows at centers including St. Jude Children's Research Hospital and Dana-Farber Cancer Institute, and informed compassionate-use considerations reviewed by Food and Drug Administration and ethics panels at leading hospitals. The dataset accelerated target validation efforts at academic drug discovery centers such as Cold Spring Harbor Laboratory and biotechnology collaborations connected to Broad Institute.

Data Sharing and Resources

The project emphasized open-access deposition of processed datasets to community resources patterned after repositories like European Genome-phenome Archive, dbGaP, and project aggregators maintained by National Institutes of Health. Data distribution supported secondary analyses by researchers at Harvard Medical School, Stanford University, and international teams at University College London and Karolinska Institutet. Analytical toolkits and variant catalogs were integrated into platforms created by groups at Broad Institute and Wellcome Trust Sanger Institute, enabling meta-analyses with datasets from International Cancer Genome Consortium and The Cancer Genome Atlas Research Network.

Criticisms and Limitations

Critiques from investigators at institutions including Yale School of Medicine and policy scholars at Georgetown University highlighted cohort size constraints relative to adult consortia like The Cancer Genome Atlas, challenges in representing global pediatric diversity compared with studies from Karolinska Institutet and UCL, and limitations in linking genomic alterations to long-term outcomes captured by registries at National Cancer Institute. Methodological limitations noted parallels to broader sequencing debates involving 1000 Genomes Project and raised concerns about variant interpretation that groups at Cold Spring Harbor Laboratory and Broad Institute continue to address. Ethical discussions involving consent and data reuse engaged committees at St. Jude Children's Research Hospital, Washington University School of Medicine, and advisory bodies connected to National Institutes of Health.

Category:Medical research projects